Conference Day Two
Thursday 18th July 2024
8:00 am
Check-In & Coffee
8:55 am Chair’s Opening Remarks
Gain Clarity on the IVDR Pathway to De-Risk Submissions for Accelerated Approvals
9:00 am Fireside Chat: Strategising for Routine Adoption of Liquid Biopsy Testing by Addressing IVDR, Reimbursement Issues & Other Challenges to Enhance Commissioning
Synopsis
• How does the recent European IVDR landscape needs to ensure regulatory alignment whilst addressing unmet patient needs?
• How to expand the application of liquid biopsies beyond special cases, where the value would be significant in bringing the right treatment to the patients faster?
• How to address the ever-growing reimbursement challenges for the routine usage of liquid biopsies?
• How to address the lag between a drug being launched and a diagnostic being reimbursed to ensure patient care is not compromised in the process?
10:00 am
Morning Networking Break
Enhancing Consensus & Collaboration to Reduce Fragmentation Through Shared Guidelines for Broader Adoption of Liquid Biopsy Assays Across Europe
11:00 am Overcoming Challenges in Clinical Adoption of Liquid Biopsies across Europe Through Innovative Strategies to Enhance Test Utilization & Patient Access
Synopsis
• What are the main challenges in clinical adoption of liquid biopsies across European countries?
• How to tackle fragmentation: How to create cohesion across countries to ensure that differences do not slow down innovation?
• How to collect clinical data to sustain the usage of liquid biopsies across Europe?
11:30 am Demonstrating the Need for Multidisciplinary Collaboration to Combat Lack of Physician Awareness & Call for Local & National Advocacy & Policy to Promote the Adoption of Liquid Biopsies
Synopsis
• Analysing how oncologists and frontline clinicians may lack familiarity with liquid biopsy technology, its benefits, and its implications for patient care
• Establishing multidisciplinary cross functional groups within hospitals to facilitate consensus building and decision making for the integration of liquid biopsy into patient care
• Building consensus among healthcare professionals and establishing protocols for incorporating liquid biopsy into clinical practice
12:00 pm Optimising Liquid Biopsy Access Through Inclusive Payment Models, Sample Handling Solutions & Global Access Strategies
Synopsis
• Integrate multiple payers into the payment structure such as the health insurer, the taxpayer, the patient, private health, public health
• How to overcome the single site testing reluctance to send samples outside of clinical sites?
• Navigating whether samples need to be shipped outside of a country or outside of the EU and what are the barriers in access?
12:30 pm
Networking Lunch
Optimising Pre-Analytics & Sample Handling for Reliable Molecular Analysis to Improve Patient Management
1:30 pm Roundtable Discussion: Empowering Precision Medicine by Integrating Novel Biomarkers & Strategic Approaches for Enhanced Cancer Patient Management & Treatment Optimization
Synopsis
• Engage in discussions on strategies to standardize pre-analytics handling of liquid biopsy samples, ensuring uniformity and reliability in molecular analysis across diverse clinical settings
• Dive deep into the development of agnostic assays utilising innovative techniques such as DNA fragment analysis and methylation markers, exploring their potential to enhance cancer patient follow-ups and treatment outcomes
• Delve into the validation process of circulating tumor DNA (ctDNA) as a pivotal marker for patient management across multiple cancer types, discussing its utility, challenges, and implications for precision oncology
2:30 pm Developing New Strategies & Biomarkers for Cancer Patient Follow Ups
Synopsis
• Ensuring appropriate pre-analytics handling of LB samples
• Developing appropriate agnostic assays based on DNA fragment analysis and methylation markers.
• Validation of ctDNA as a pertinent marker for patient management/ patient follow up in several cancers
3:00 pm Advancing Liquid Biopsy Assays for Workflow Standardization & Early Detection to Generate Consistency in Results & Empower Precision Treatments
Synopsis
• Harmonising liquid biopsy assays and processing protocols to address variations in sample handling timeframes
• Investigating how to enhance the stability and longevity of ctDNA samples for reliable molecular analysis
• Enabling broad access to liquid biopsy assays and global harmonization of regulatory requirements